The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Systemic Treatment of Adult Atopic Dermatitis: A Review
Open accessAbstract
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Due to its chronic nature and frequently occurring relapses, AD has a substantial effect on patients' quality of life, often requiring long-term systemic treatment, especially in adult patients, who are more frequently refractory to adequate topical treatment with mid- to high-potent corticosteroids and/or calcineurin inhibitors. Therefore, treatment with systemic therapies is often needed to take control of the disease, prevent exacerbations and improve quality of life. However, data regarding systemic treatment effectiveness and long-term safety in adult patients with AD are insufficient. Indeed, standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries. This review focuses on the use of systemic treatments in adult AD patients analyzing published literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 2×
“improvement in the serum levels of Th2-associated biomarkers, such as thymus and activation-regulated chemokine (TARC), total IgE and eosinophil counts [136] and by the improvement of the AD molecular signature tested with transcriptomic analyses of pre- and post-treatment skin biopsy specimens from patients with mode…”
BackgroundNograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627 · cited 1×
“Therefore, ustekinumab may be useful in AD, which is increasingly recognized as a Th2- and Th22-centered disease with some contributions of the Th17 and Th1 axes [97].”
BackgroundHeil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197
Failure of omalizumab for treatment of severe adult atopic dermatitis
Krathen, R. A., & Hsu, S. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.02.014 · Cited by 172
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
Samrao, A., Berry, T. M., Goreshi, R., & Simpson, E. L. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.812 · Cited by 166
Omalizumab for atopic dermatitis: case series and a systematic review of the literature
Holm, J. G., Agner, T., Sand, C., & Thomsen, S. F. (2017) · International Journal of Dermatology · doi:10.1111/ijd.13353 · Cited by 71
Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab
Zink, A., Gensbaur, A., Zirbs, M., Seifert, F., Suarez, I., Mourantchanian, V, Weidinger, S., Mempel, M., Ring, J., & Ollert, M. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2165 · Cited by 67
Cited by
de Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479
Review of Tralokinumab in the Treatment of Atopic Dermatitis
Singh, R., Taylor, A., Shah, M. A., Strowd, L. C., & Feldman, S. R. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221105686 · Cited by 10
Metadata
- Authors
- Megna, M., Napolitano, M., Patruno, C., Villani, A., Balato, A., Monfrecola, G., Ayala, F., & Balato, N.
- Venue
- Dermatology and Therapy
- Published
- 2016-12-26
- Volume
- 7
- Issue
- 1
- Pages
- 1-23
- ISSN
- 2190-9172 (ISSN-L)
- 2193-8210
- OpenAlex
- W2566687596
- Cited by
- 159
- References
- 7
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic Treatment of Adult Atopic Dermatitis: A Review. https://app.cochat.ai/papers/10.1007/s13555-016-0170-1
- The paper
- Megna, M., Napolitano, M., Patruno, C., Villani, A., Balato, A., Monfrecola, G., Ayala, F., & Balato, N. (2017). Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatology and Therapy. https://doi.org/10.1007/s13555-016-0170-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.